Orchard Therapeutics plc - ADR logo

ORTX

Orchard Therapeutics plc - ADR

$0.58

Earnings Summary

Revenue
$4.37Mn
Net Profits
$-50.92Mn
Net Profit Margins
-1165.66%

Highlights

Revenue:

Orchard Therapeutics plc - ADR’s revenue jumped +Inf% since last year same period to $4.37Mn in the Q2 2022. On a quarterly growth basis, Orchard Therapeutics plc - ADR has generated -20.93% fall in its revenue since last 3-months.

Net Profits:

Orchard Therapeutics plc - ADR’s net profit fell -39.08% since last year same period to $-50.92Mn in the Q2 2022. On a quarterly growth basis, Orchard Therapeutics plc - ADR has generated -14.94% fall in its net profits since last 3-months.

Net Profit Margins:

Orchard Therapeutics plc - ADR’s net profit margin jumped NaN% since last year same period to -1165.66% in the Q2 2022. On a quarterly growth basis, Orchard Therapeutics plc - ADR has generated -45.37% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Orchard Therapeutics plc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.26
EPS Estimate Current Year
-0.26

Highlights

EPS Estimate Current Quarter:

Orchard Therapeutics plc - ADR’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 7.14% jump from last quarter’s estimates.

EPS Estimate Current Year:

Orchard Therapeutics plc - ADR’s earning per share (EPS) estimates for the current year stand at -0.26.

Key Ratios

Key ratios of the Orchard Therapeutics plc - ADR post its Q2 2022 earnings

Return on Assets (ROA)
-0.28
Return on Equity (ROE)
-0.82
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Orchard Therapeutics plc - ADR’s return on assets (ROA) stands at -0.28.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Orchard Therapeutics plc - ADR’s return on equity (ROE) stands at -0.82.

Dividend Per Share (DPS):

Orchard Therapeutics plc - ADR declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.26
-0.35
-34.62%

Company Information

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. The company's ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK's rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Organisation
Orchard Therapeutics plc - ADR
Headquarters
108 Cannon Street, London, United Kingdom
Employees
2.02K
Industry
Health Technology